What is Viridian Therapeutics, Inc.'s revenue?

Viridian Therapeutics, Inc. (VRDN) generated $70.9M in revenue over the trailing twelve months, up 23382.8% year over year.

Is Viridian Therapeutics, Inc. profitable?

Viridian Therapeutics, Inc. is not currently profitable: it reported a net loss of $360.6M over the trailing twelve months, a -508.5% net margin.

What are Viridian Therapeutics, Inc.'s profit margins?

Gross margin is 36.3% and operating margin is -543.9%, with a -508.5% net margin.

Where does Viridian Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Viridian Therapeutics, Inc. VRDN Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$70.92M+0.1%	$70.85M+0.1%	$70.79M+23,110%	$305K+1.0%	$302K0.0%
Research and development	$339.73M+0.2%	$338.93M+5.4%	$321.68M+5.6%	$304.58M+11.1%	$274.15M+15.1%
Selling, general and administrative	——	——	——	——	$62.92M+3.0%
Total operating expenses	$456.62M+5.2%	$434.24M+8.9%	$398.91M+7.3%	$371.89M+10.3%	$337.31M+12.7%
Operating income	-$385.7M-6.1%	-$363.4M-10.8%	-$328.12M+11.7%	-$371.59M-10.3%	-$337.01M-12.7%
Operating margin	-543.9%-30.9pp	-512.9%-49.4pp	-463.5%+121,368pp	-121,831.1%-10,240pp	-111,591.1%-12,573pp
Interest expense	$7.82M+59.4%	$4.91M+129%	$2.14M+1.5%	$2.11M-3.8%	$2.19M-1.7%
Interest income	$27.73M+1.2%	$27.4M-2.6%	$28.13M-6.6%	$30.12M-4.0%	$31.37M-1.3%
Other income (expense), net	$25.11M+20.7%	$20.79M-20.5%	$26.15M-5.0%	$27.52M-4.1%	$28.69M-1.4%
Net income	-$360.59M-5.3%	-$342.6M-13.5%	-$301.97M+12.2%	-$344.06M-11.6%	-$308.32M-14.2%
Net margin	-508.5%-24.9pp	-483.6%-57.0pp	-426.6%+112,380pp	-112,806.9%-10,715pp	-102,092.4%-12,705pp
Diluted earnings per share	——	——	——	——	——
Basic earnings per share	——	——	——	——	——
Weighted-average shares, diluted	——	——	——	——	——
Weighted-average shares, basic	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$361.39M-5.6%	-$342.14M-13.1%	-$302.54M+11.9%	-$343.45M-11.6%	-$307.71M-13.8%
Derivative, Gain (Loss) on Derivative, Net	——	——	——	——	$0—
Net unrealized gains (losses) on securities still held	-$806K-276%	$457K+180%	-$569K-193%	$612K0.0%	$612K+276%
Other income, net	-$2.34M-37.4%	-$1.7M-1,155%	$161K+133%	-$487K—	——
Research and development expense	$339.73M+0.2%	$338.93M+5.4%	$321.68M+5.6%	$304.58M+11.1%	$274.15M+15.1%
EBIT	-$385.7M-6.1%	-$363.4M-10.8%	-$328.12M+11.7%	-$371.59M-10.3%	-$337.01M-12.7%
EBITDA	-$385.23M-6.1%	-$362.94M-10.8%	-$327.66M+11.7%	-$371.1M-10.3%	-$336.49M-12.7%
EBITDA	-$385.23M-6.1%	-$362.94M-10.8%	-$327.66M+11.7%	-$371.1M-10.3%	-$336.49M-12.7%
EBITDA margin	-543.2%-30.9pp	-512.3%-49.4pp	-462.9%+121,210pp	-121,672.8%-10,251pp	-111,421.5%-12,582pp
EBIT	-$385.7M-6.1%	-$363.4M-10.8%	-$328.12M+11.7%	-$371.59M-10.3%	-$337.01M-12.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Viridian Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s revenue?: Viridian Therapeutics, Inc. (VRDN) generated $70.9M in revenue over the trailing twelve months, up 23382.8% year over year.
Is Viridian Therapeutics, Inc. profitable?: Viridian Therapeutics, Inc. is not currently profitable: it reported a net loss of $360.6M over the trailing twelve months, a -508.5% net margin.
What are Viridian Therapeutics, Inc.'s profit margins?: Gross margin is 36.3% and operating margin is -543.9%, with a -508.5% net margin.
Where does Viridian Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.